Fig. 1

Workflow of our article: In the first step, two datasets (SMC & KUL3) were selected, and the gene signatures of the disease were calculated by the ASAP platform. Also, five common drugs for the treatment of colorectal cancer were selected from the NCI website, and their gene signatures were obtained using the iLINCS database.Then, with three different approaches, these gene signatures were checked by the iLINCS database, and chemical compounds that have the potential to treat colorectal cancer were selected. These compounds were filtered using various articles and pharmaceutical databases, and finally, 12 drugs were selected that had two conditions: being approved by institutions such as the FDA and not being introduced as a cancer treatment in any study so far. Four drugs were selected, and their cytotoxic effect on cancer cell lines (HT29 and HCT116) was evaluated by MTT assay and real-time PCR.